CeloNova BioSciences, Inc.

Pioneers in Cardiovascular Innovation

Our Company

CeloNova BioSciences, Inc. is an innovative global medical device leader transforming the treatment of cardiovascular disease and addressing the treatment gap in patients at high risk of bleeding.

CeloNova BioSciences develops, manufactures and markets a family of products based upon its novel Polyzene-F nanocoating technology. This next-generation nanocoating is the result of years of rigorous scientific research and German-engineering and has been widely published in numerous academic articles to date.

In 2015, CeloNova BioSciences interventional radiology product lines were acquired by Boston Scientific. Read more here. Moving forward, CeloNova BioSciences is looking to develop new PzF applications for implantable medical devices that will help patients and change the practice of medicine around the world.

Celonova BioSciences Inc.

Shaping the Future of Quality & Safety

In January 2018, CeloNova became one of a handful of companies in the U.S. selected to support advancements in medical device quality and safety through partnership with the FDA’s Case for Quality Voluntary Improvement Program (CFQ VIP).

This program identifies device manufacturers that consistently produce high-quality devices to help better focus FDA resources and promote best practices to help other manufacturers raise their level of quality and safety. Through the program’s partnership, CeloNova aims to further advance quality of care in patients in the U.S. 1

CeloNova was recently featured in a case study by the CMMI Institute for our dedication to compliance and quality, and you can read more about our journey and success by reading the full CMMI CeloNova Case Study, and also in a recent CMMI blog post.


CeloNova Named Top 10 Cardiovascular Device Companies of 2019 by MedTech Outlook

In April of 2019, MedTech Outlook recognizes CeloNova BioSciences, Inc. as a pioneer at the forefront of cardiovascular innovation by naming the company as one of the top 10 cardiovascular companies of 2019.

CeloNova’s foundation of innovation has led to the successful manufacturing and marketing of a family of products, including the COBRA PzF NanoCoated Coronary Stent (NCS), based upon its proprietary Polyzene-F (PzF) nanocoating technology, a revolutionary surface coating designed to optimize implant interaction within the body.Through its commitment to PzF innovation, CeloNova is transforming clinical practice and promoting positive outcomes in patients around the world.

Top 10 CardioVascular Device Companies - 2019 Logo - Jpeg

Committed to Compliance and Ethics

CeloNova BioSciences Inc. is committed to high standards of compliance and ethics.  CeloNova abides by the Advanced Medical Technology Association (AdvaMed) Code of Ethics on Interactions with Health Care Professionals, which provides a guide for ethical and  lawful  business  practices  for  the  medical  technology  industry.  CeloNova’s compliance program is established to prevent and detect violations of the AdvaMed code, company policies, and applicable laws.  The complete AdvaMed Code of Ethics can be found HERE.

Board Members

Carl St. Bernard

CEO, Board Member

St. Bernard joins the company from Tryton Medical where he held the role of President and CEO, leading the company’s commercialization efforts in the highly competitive coronary stent market. St. Bernard has also an extensive track record growing businesses across a variety of fields including pharmaceuticals, consumer health products and diagnostic markets. St. Bernard’s prior experience includes Vice President at Johnson & Johnson Vision (formerly Abbott Medical Optics), Vice President of North American Marketing & Sales for LifeCell and Vice President at Cordis where he led the commercial operations for the cardiovascular and endovascular businesses in the U.S.

Thomas (Tim) Lyles, JD

Board Member

Mr. Lyles is President of Mission City Management, Inc. and MedCare Investment Funds. Mr. Lyles has managed an investment portfolio for over twenty years, including both public and large private companies. He also serves on numerous for-profit and non-profit Boards of Directors. Mr. Lyles’ primary responsibility is President of a private holding company, which oversees both strategic and operational issues for various fund portfolios. Mr. Lyles has helped organize each fund in the MedCare Investment Funds group and has served as President of each fund since 1991. As a founding partner, Mr. Lyles was an active member of management in founding Renal Care Group along with Dr. Jacobson and the late Sam Brooks. Mr. Lyles, through his role as President of MedCare Investment Funds, has founded and established numerous health care companies. From 1984 to 1989, Mr. Lyles was an Attorney with the law firm of Haynes and Boone in Dallas, Texas. During 1986 and 1987, he taught Real Estate Financing at Southern Methodist University in Dallas. From 1983 to 1984, he was appointed a Briefing Attorney for the Chief Justice of the Supreme Court of Texas. Tim received his Juris Doctorate Cum Laude from SMU School of Law. Prior to attending law school, he was employed by KPMG Peat Marwick. Mr. Lyles earned an accounting degree from Texas A & M University, where he graduated Summa Cum Laude. In addition, Mr. Lyles is a Certified Public Accountant and has written material for the Texas State Bar and has been a speaker for the State Bar of Texas and the Dallas Bar.

Harry Jacobson, MD

Board Member

Dr. Jacobson is former Vice Chancellor for Health Affairs at Vanderbilt University and Chief Executive Officer of Vanderbilt University Medical Center (VUMC). During his more than 11 years of tenure, VUMC revenues grew from $750 million to $2.5 billion, while delivering superior care at substantially lower costs than those in similar hospitals. Its federally-funded NIH research program moved from 24th to the top 10 in the country, and over $1 billion of newly-constructed research and patient care facilities were opened during his tenure. Dr. Jacobson has been a successful investor and entrepreneur, as well, having founded or co-founded more than ten companies, including Contact Software, Renal Care Group and Ambulatory Services of America. He has been both a formal and informal advisor to several venture and private equity funds. He formerly served on the Board of Directors of Kinetic Concepts, Inc. and Merck. Dr. Jacobson currently serves as Chairman of the Board of MedCare Investment Funds, a privately-held healthcare investment group. Harry received his Doctor of Medicine degree from the University of Illinois in 1972 and completed his medical residency at Johns Hopkins Hospital and specialty training in nephrology at the University of Texas Health Science Center in Dallas.

Jason Cone

Board Member

Jason Cone is President of a private consulting and holding company which oversees a variety of investment and philanthropic interests.  Previously, he served as General Counsel, and later as President and Chief Executive Officer, of CeloNova BioSciences, Inc.  Mr. Cone has 22 years of experience working with a wide variety of business, healthcare and financial clients. Mr. Cone’s education includes a Juris Doctorate with Honors from the University of Texas School of Law and a Bachelor in Business Administration from Baylor University.

Gregory Oberholtzer

Board Member

Gregory Oberholtzer, Senior Managing Director, WP Global Partners, has over 32 years of broad investment advisory experience with a focus on alternative asset management and financial product structuring for institutional clients.

Prior to joining WP Global, he was a Director of WestAM, where he was responsible for their small and middle market buyouts, special situations, and co-investments, and was a member of the Private Equity Executive Committee and Investment Committee. Prior to WestAM, Mr. Oberholtzer previously served as the Managing Director and Portfolio Manager of Forstmann-Leff International’s (FLI) Global Derivatives Group and was a Senior Vice President of Products and Strategies. Prior to FLI, Mr. Oberholtzer was a Director of Jefferies Analytical Trading Group at Jefferies Group, where he was involved in product structure and fund management in equities and listed derivatives. Mr. Oberholtzer has served as the president of two private financial services companies and was active in a successful family business for several years.

He is a board member or observer of Australis, BrightFarms, Illumitex, Monogram Foods, and VoloAgri, among other portfolio companies, and serves as an advisory board member of more than two dozen invested funds. He holds a B.B.A. from George Washington University.

Nurture Your Unique Potential

At CeloNova BioSciences, you’ll have the opportunity to further your potential by joining a team of cutting edge cardiovascular innovators and leaders dedicated to transforming the treatment of coronary artery disease. Here you’ll discover challenges that develop you professionally, allowing you to explore a customer-centric culture with a hunger for innovation and improvement.

If you feel you have what it takes to join our team, we encourage you to review the open positions listed below and submit your resume and cover letter to HR@celonova.com.  Please include the title of the opportunity in the subject line of the email.

We look forward to hearing from you!

Nuture your potential

Job Listings

Regional Account Manager (Orlando, Florida)

In this role as Regional Account Manager- Orlando, Florida you will be responsible for driving growth in the Orlando/Tampa/Jacksonville area for a new category of coronary stent called COBRA PzF NanoCoated Coronary Stent (NCS). Your goal is to develop and manage key accounts and customer relationships in this territory. To be successful in your role you will need knowledge in interventional cardiology, Cath Lab experience, strong sales and training skills and the ability to promote trust and respect within the cardiology community in your territory. With this winning combination and our support, you will successfully drive product growth and positive clinical outcomes as you guide physicians and staff on the safe and effective treatment of their PCI patients with COBRA PzF NCS.

Learn More